Psychological effect of cervical cancer screening when changing primary screening method from cytology to high-risk human papilloma virus testing by Andreassen, Trude et al.
Psychological effect of cervical cancer screening when changing
primary screening method from cytology to high-risk human
papilloma virus testing
Trude Andreassen 1,2,3, Bo T. Hansen1, Birgit Engesæter1, Dana Hashim1,4, Nathalie C. Støer 5, Ameli Tropé1,
Kåre Moen3, Giske Ursin1,2,6 and Elisabete Weiderpass1,7,8,9
1Cancer Registry of Norway, Institute of PopulationBased Cancer Research, Oslo, Norway
2Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
3Institute of Health and Society, University of Oslo, Oslo, Norway
4Department of Haematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
5Oslo University Hospital, Norwegian National Advisory Unit on Women’s Health, Oslo, Norway
6University of Southern California, Department of Preventive Medicine, Los Angeles, CA
7Folkhälsan Research Centre, Genetic Epidemiology Group, and Faculty of Medicine, Helsinki University, Helsinki, Finland
8Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway
9Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
From 2015, Norway has implemented high-risk human papilloma virus (hrHPV) testing in primary screening for cervical cancer. Women
aged 34–69 years, living in four counties, have been pseudo-randomly assigned (1:1 randomization) to either hrHPV testing every
5 years (followed by cytology if hrHPV is positive), or cytology testing every 3 years (followed by hrHPV testing if low-grade cytology is
detected). We compared anxiety and depression scores among participants by screening arm and results. In total, 1,008 women
answered a structured questionnaire that included the validated Patient Health Questionnaire-4 (PHQ-4). The Relative Risk Ratio (RRR)
of mild vs. normal anxiety and depression scores, and moderate/severe vs. normal anxiety and depression scores, were estimated by
multinomial logistic regression with 95% confidence intervals (95% CIs). Compared to women who were screened with cytology,
women randomized to hrHPV testing were not more likely to have mild anxiety and depression scores (RRR 0.96, CI 0.70–1.31) nor
more likely to have moderate/severe anxiety and depression scores (RRR 1.14, CI 0.65–2.02). Women with five different combinations
of abnormal screening test results were not more likely to have mild or moderate/severe vs. normal anxiety and depression scores
than women with normal screening results. The likelihood of having abnormal long-term (4–24 months after the screening) anxiety or
depression scores among women 34 years and older was not affected by screening method or screening results. The results of our
study suggest that a change to hrHPV testing in primary screening would not increase psychological distress among participants.
Introduction
The Norwegian Cervical Cancer Screening Programme
(NCCSP) has been national since 1995. It is managed by the
Cancer Registry of Norway—Institute of Population based
Cancer Research (CRN), which reminds women aged
25–69 years to have a cervical cytology taken every 3 years.1
From 2005, high-risk human papilloma virus (hrHPV)
testing has been used as a triage test in the screening
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programme as part of follow-up among women with abnor-
mal low-grade cytology.2
Between 2015 and 2018, a national project implemented
hrHPV testing in primary screening3 (i.e. as the first screening
test taken) among women in four counties (Rogaland, Horda-
land, Sør-Trøndelag, and Nord-Trøndelag). A prerequisite from
the National Council for Priority Setting prior to the introduction
of the implementation project was that hrHPV testing would not
lead to increased anxiety and depression among screening partici-
pants.4 The most common mental health conditions in the gen-
eral population are anxiety and depression.5–7 The prevalence of
these conditions in Norway is similar to other countries in
Europe and the United States:8 about 25% of the Norwegian
women will be affected by an anxiety disorder at some point in
life,9 and around 20% will experience depression.8 Women may
experience increased anxiety and depression at the time of any
cervical examination,10 but it is unknown whether a change from
cytology to hrHPV testing in primary screening will increase anx-
iety and depression levels among screening participants.
A study conducted in Norway prior to the implementation
project indicated that a switch to hrHPV testing was unlikely to
affect women’s anxiety nor to reduce their participation in
NCCSP.11 A limitation of the study was that it was not carried
out in a real-life situation but merely asked participants how they
assumed they would experience the two different screening
methods. Research carried out in Ireland12 found that the emo-
tional impact of hrHPV testing in screening participants was mod-
est and that women’s concerns were related to screening test
results more than to the screening method used. Yet, the conclu-
sion drawn by these two studies are at odds with those drawn by
other researchers, suggesting that hrHPV-based screening pro-
grammes may be associated with increased anxiety and stress and
to increased concerns about having a sexually transmitted infec-
tion.13,14 Hence, the relationship between hrHPV testing in pri-
mary screening and women’s mental health is unresolved.
Moreover, the majority of studies addressing this issue have been
performed in the setting of secondary hrHPV testing (the second
test taken after cytology).15,16 We took advantage of the ongoing
implementation project in the NCCSP to perform a cross-sectional
study comparing anxiety and depression scores among women
screened with hrHPV testing or cytology in primary screening.
Objectives
Our objectives were to compare long-term (4–24 months after
the screening) anxiety and depression scores between women
allocated to the two screening arms, cytology or hrHPV test.
Subjects and Methods
The implementation project of hrHPV testing in primary
screening
The implementation project of hrHPV testing in primary
screening is pseudo-randomized, that is, allocation to screen-
ing method is decided by the participant’s date of birth being
an odd or an even day. Women aged 34–69 years living in
one of the four implementation counties were allocated either
to (i) hrHPV testing with a 5-year screening interval (followed
by cytology if hrHPV positive) or to (ii) cytology with a
3-year screening interval (followed by hrHPV testing in case
of low-grade cytology).3,17 hrHPV testing was performed on
liquid-based cytology samples. Figure 1 summarizes the algo-
rithm for hrHPV and cytology screening used in the imple-
mentation project. Women with a negative hrHPV test in the
hrHPV arm, received an additional letter from the NCCSP
with information about the extended screening interval that fol-
lowed a hrHPV negative test result. Women aged 25–33 years
were not included in the implementation project but continued
to be screened with cytology every 3 years due to the generally
high hrHPV prevalence with no clinical relevance in this age
category.18
Study population
As of September 2017, 168,201 women had participated in the
implementation project according to the Cancer Registry of
Norway, which records all screening tests taken as part of the
NCCSP unless participating women have actively objected to
their screening data being registered.19 Among these, we iden-
tified women who had undergone cervical cancer screening
between February 15, 2015 and September 15, 2016 and ran-
domly sampled 500 women from the cytology arm and
500 women from the hrHPV arm. In addition, we randomly
oversampled 500 women who had had a positive cytology in
the cytology arm, and 500 women who had had a positive
hrHPV test in the hrHPV arm. We did so to compare anxiety
and depression scores among women with positive screening
test results in the two arms. Thus, a total of 2,000 women
were sampled for our study (Fig. 2).
These women received a structured questionnaire by postal
mail in January or February 2017, 4–24 months after they had
been informed about their last screening test result. An infor-
mation leaflet and a prepaid return envelope were enclosed
with the questionnaire. The initial response rate was 39%
(n = 789). The questionnaire was resent to nonresponders after
one month, resulting in a total response rate of 51%
What’s new?
Norway is one of the first countries to implement high-risk human papilloma virus (hrHPV) testing in primary cervical-cancer
screening. Does this newer type of testing impact the emotional well-being of patients? In this study, the authors found no
significant difference in either anxiety or depression scores between the viral-screening arm and standard cytology screening.
These findings could be useful for other countries considering implementing hrHPV testing, and are reassuring for the ongoing
implementation process in Norway.
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(n = 1,014). We excluded six women who had answered the
same questionnaire twice with dissimilar answers, leading to a
50% response rate (n = 1,008). Nine women with unsatisfactory
cytology results in the cytology arm were also excluded from
the analysis (Fig. 2). The registration of screening activity and
screening results in the NCCSP made it feasible to link com-
pleted questionnaires to objective data on screening test results.
Questionnaire
The questionnaire (in Norwegian language [shown in the Sup-
porting Information 1]) included the Patient Health
Questionnaire-4 (PHQ-4) for anxiety and depression. 5,20 The
PHQ-4 has been developed from two larger and validated
anxiety and depression measure instruments: the 7-itemed
GAD-7 measuring anxiety,21 and the 9-itemed PHQ-9 mea-
suring depression.22 PHQ-4 incorporates the core criteria for
anxiety and depression from these instruments and has been
validated for use as a screening tool.5,20 A meta-analysis23 has
found that combining anxiety and depression items into one
tool gives better results than single-item screening tools. The
PHQ-4 consists of two questions regarding anxiety and two
regarding depression. It asks: “Over the last two weeks, how
often have you been bothered by the following problems” and
then specifies these as “feeling nervous, anxious, or on the
edge,”” not being able to stop control worrying,” “feeling down,
depressed or hopeless” and “having little interest or pleasure in
doing things”. For each of these items, responses were scored
as: 0 (“not at all”), 1 (“several days”), 2 (“more than half the
days”) or 3 (“nearly every day”), with a total score range from
0 to 12. Anxiety and depression was graded as none (total score
from 0 to 2), mild (3–5), moderate (6–8) and severe (9–12).
The questionnaire also asked about age, marital status and
educational level. In addition, nonvalidated questions were
asked about the study participants´ experience with the
NCCSP (e.g. have you ever received a letter from the Cancer
Registry reminding you to take a screening test?), knowledge
related to cervical cancer (e.g. before reading the attached
information letter, did you know that a cervical cytology test
Figure 1. The Norwegian cervical cancer screening algorithm for primary cytology and primary hrHPV screening used in the period from 2015
to 2018 when implementing hrHPV testing in four counties among women aged 34–69 years. [Color figure can be viewed at
wileyonlinelibrary.com]
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can reveal cellular changes that untreated can lead to cervical
cancer?) knowledge related to HPV (e.g. before you read
about human papillomavirus (HPV) in the attached informa-
tion letter, did you know that HPV can cause cancer?), their
last screening test results (e.g. what was the results of your last
screening test?), and the type of screening method that had
been used at their last screening attendance (e.g. what screen-
ing method was used when your last screening test was
taken?) The questionnaire was piloted in two rounds in 2016
among women working at CRN.
Ethical considerations
The Privacy Ombudsman and Data Protection Officer at Oslo
University Hospital in Norway, assessed and recommended
the study (case number 2016/15743). The information leaflet
explained the study, including the registry linkages that would
take place, and that answering and returning the questionnaire
would be considered informed consent to participate in the
study. Each questionnaire was assigned a unique ID number*,
from 1 to 2000, and was linked to the objective clinical screen-
ing data at the NCCSP.
Statistical analysis
Statistical differences between women in the two screening
arms (cytology and hrHPV) were assessed using χ2 test for
categorical outcomes and Student’s t-test for the continuous
variable, age. Anxiety and depression scores were categorized
as normal (values ≤2), mild (values 3–5), or moderate/severe
(values >5), and compared between the two screening arms
and among persons with different screening test results. We
estimated the relative risk ratio (RRR) of scoring (a) mild vs.
Figure 2. Flow diagram of study participants and their previous screening results. *We identified women from the pilot project with the
following strata: 500 women from the cytology arm, 500 women from the hrHPV arm, 500 with a positive cytology results from the cytology
arm and 500 women with a positive hrHPV test results from the hrHPV arm. Total 2000 women: **nine women with inconclusive screening
test results in the cytology arm are excluded from the analysis. [Color figure can be viewed at wileyonlinelibrary.com]
*In Norway, all citizens are given a unique personal identification
number when born. To ensure the anonymity of the study
participants, we did not use this personal identification number on
the questionnaires, rather a unique ID number.
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normal and (b) moderate/severe vs. normal on anxiety and
depression by multinomial logistic regression with 95% confi-
dence intervals (95% CI).
The association between the two screening arms and
between the specific screening results and anxiety and depres-
sion were estimated in two separate models. These models were
adjusted for demographic characteristics that differed between
women in the two screening arms (Table 1): marital status
(married/cohabiting, single/divorced/widowed) and place of
birth (Norway, all other countries). Based on findings of prior
studies of the association between screening method and psy-
chological distress,11,24,25 we also included age group (34–44,
45–54, ≥55) and educational level (≤13 years, > 13 years) as
covariates in the two multinomial logistic regression models.
The goodness of fit of the multinomial crude models was evalu-
ated by testing the goodness of fit in the two corresponding
logistic regression models for mild vs. normal and moderate/se-
vere vs. normal using the Hosmer and Lemeshow test.26
The elapsed time from information about screening results
to answering the questionnaire was categorized (4 months to
1 year, 1–2 years). We tested for interactions between the
elapsed time and the two screening arms and between elapsed
time and the specific screening results by including interaction
term in the models, in addition to performing stratified
analyses.
The sample in the univariate and multivariate analyses
vary from 966 to 1,008 women, due to missing values. All
tests were two-sided with a 5% significance level. All statistical
analyses were conducted using the Stata statistical software
package (version 14.2).
Definitions of cervical cancer screening test results
Women taking part in the implementation project can, when
the NCCSP’s guidelines 27 are followed, receive seven† differ-
ent combinations of screening test results:
In the cytology arm:
1. Cytology normal
2. ASC-US‡ or LSIL§ and hrHPV negative
3. ASC-US or LSIL and hrHPV positive
4. High-grade cytology
In the hrHPV arm:
1. hrHPV negative
2. hrHPV positive and normal cytology
3. hrHPV positive and ASC-US or more severe
Results
Among the 1,008 women who answered the questionnaire,
521 (52%) were from the cytology arm and 487 (48%) from
the hrHPV arm. The mean age was 50.5 years (SD  9.7) in
the cytology arm and 51.2 years (SD  10.1) in the hrHPV
arm. The frequency of abnormal primary cytology and posi-
tive primary hrHPV tests results were 54% and 53%,** respec-
tively (Table 1).
Age, attained education, duration of residency in Norway,
previous screening test results and the time that had elapsed
from a woman received her last screening test result until she
answered the questionnaire, were similar in the two arms
(Table 1). However, women in the hrHPV arm were signifi-
cantly more often single/divorced/widowed (p = 0.04) and
more often born in Norway (p = 0.05) than women in the
cytology arm.
The knowledge that participation in screening can detect
precancerous lesions and prevent cervical cancer was similar
and very high in both study arms (97% and 98% of women in
the cytology and the hrHPV arm, respectively [p = 0.30]).
Fewer (66%) in the cytology arm than in the hrHPV arm
(72%) knew that an hrHPV infection can cause cervical cancer
(p = 0.02). When women were asked what screening-method
had been used the last time they were screened, the answers
differed by arms: 35% of those in the cytology arm, and 39%
of those in the hrHPV arm, answered correctly, whereas 4%
in the cytology arm and 20% in the hrHPV arm answered this
question incorrectly (p < 0.0001). Hence, the majority of
women were unable to identify the analysis method used the
last time they were screened (61% of women in the cytology
arm and 41% in the hrHPV arm [p < 0.0001]). When asked
about the results of their last screening test, fewer in the cytol-
ogy arm (66%) reported this correctly than in the hrHPV arm
(82%) (p < 0.0001). 53% of women in the cytology arm and
58% of women in the hrHPV arm indicated that they would
have had a screening test performed on their own initiative if
the screening interval were to be expanded from 3 to 5 years
(p = 0.29) (Table 1).
Anxiety and depression. The distribution of PHQ-4 scores
for anxiety and depression were nearly identical in the cytol-
ogy and the hrHPV arm: 73% had normal scores, 22% and
21% had mild scores and 5% and 6% had moderate/severe
scores, respectively (Fig. 3a). Furthermore, the distribution of
anxiety and depression scores among women with different
diagnoses is shown in Figure 3b. Most women with normal
anxiety and depression scores were to be found among
women with normal cytology in the cytology arm (34%) and
among women with negative hrHPV test in the hrHPV arm
(36%). Anxiety and depression scores among women testing
positive on the primary screening test but negative on the
second screening test were similar in the two screening arms
(women in the cytology arm having ASC-US or LSIL but
being hrHPV negative, and women in the hrHPV arm being
hrHPV positive but having normal cytology: 23%–25% had†In addition, it is also possible to receive inconclusive cytology and
hrHPV test result.
‡Atypical squamous cells of undetermined significance (ASC-US).
§Low-grade squamous Intraepithelial lesions (LSIL).
**The high percentage of abnormal screening results is due to
oversampling women with positive test results in the study cohort.
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normal scores, 7%–9% had mild scores and 2%–1% had
moderate/severe anxiety and depression scores, respectively).
Anxiety and depression among women being double positive
were also similar in the two screening arms (women in the
cytology arm having ASC-US or LSIL and being hrHPV pos-
itive, and women in the hrHPV arm being hrHPV positive
in addition to having ASC-US or more severe cytological
diagnoses: 8%–12% had normal scores, 3%–4% had mild
scores, and 1%–2% had moderate/severe anxiety and depres-
sion scores, respectively) (Fig. 3b).
Two final multivariate logistic regression models confirmed
the results from Figure 3a,b with crude percentage
Table 1. Characteristics of 1,008 women participating in the study
Total Cytology hrHPV
P-values by χ2n = 1,008 n = 521(52%) n = 487 (48%)
Age 34–44 years 301 (30%) 159 (30%) 142 (29%) 0.33
45–54 years 343 (34%) 185 (36%) 158 (32%)
55 years and older 364 (36%) 177 (34%) 187 (39%)
Marital status1 Married/Cohabiting/ 830 (82%) 441 (85%) 389 (80%) 0.04
Single/divorced/widow 175 (18%) 78 (15%) 97 (20%)
Attained education2 Up to 13 years 421 (42%) 210 (40%) 211 (43%) 0.34
More than 13 years 582 (58%) 308 (60%) 274 (57%)
Years lived in
Norway3
Less than all life 148 (15%) 83 (16%) 65 (13%) 0.25
All life 858 (85%) 437 (84%) 421 (87%)
Birthplace Norway 917 (91%) 465 (89%) 452 (93%) 0.05
Other countries 91 (9%) 56 (11%) 35 (7%)
Screening results Normal screen results 468 (52%) 240 (46%) 228 (47%) 0.81
Abnormal screen results 540 (48%) 281 (54%) 259 (53%)
Anxiety and
depression4
Normal scores 716 (73%) 370 (73%) 346 (73%) 0.88
Mild scores 206 (21%) 109 (22%) 97 (21%)
Moderate/severe scores 53 (6%) 26(5%) 27 (6%)
Time between
screening and
answering
questionnaire
4 months to 1 year 521 (52%) 216 (41%) 227 (47%) 0.10
1–2 years 487 (48%) 305 (59%) 260 (53%)
Knowledge that
screening can
prevent cervical
cancer5
Yes 980 (98%) 503 (97%) 477 (98%) 0.30
No 19 (2%) 16 (3%) 10 (2%)
Knowledge of the link
between hrHPV and
cervical cancer
Yes 695 (69%) 342 (66%) 353 (72%) 0.02
No 313 (31%) 179 (34%) 134 (28%)
Knowledge related to
last screening
method used6
Correct 364 (37%) 181(35%) 183 (39%) 0.00
Not correct 112(12%) 18 (4%) 94 (20%)
I do not know 502 (51%) 307 (61%) 195 (41%)
Knowledge related to
last screening test
results7
Correct 698 (74%) 316 (66%) 382 (82%) 0.00
Not correct 251 (26%) 166 (34%) 85 (18%)
If the screening
interval is extended
from 3 to 5 years, I
would take an
addition screening
test on my own
initiative:
More often (>5 years) 557 (56%) 277 (53%) 280 (58%) 0.292
Rarer (<5 years) 15 (1%) 6 (1%) 9 (2%)
When reminder from CRN 352 (35%) 189 (36%) 163 (33%)
Never or not sure 84 (8%) 49 (10%) 35 (7%)
13 missing.
25 missing.
32 missing.
433 missing.
59 missing.
630 missing.
759 missing.
Abbreviations: CRN: Cancer Registry of Norway; hrHPV: high-risk human papilloma virus.
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distribution of anxiety and depression scores being similar
between screening arms and between screening outcomes
(Table 2). Univariate models showed no difference in anxiety
and depression scores between women in the cytology arm
and women in the hrHPV arm (mild vs. normal anxiety and
depression scores [RRR 0.95, 95% CI 0.70–1.30] and modera-
te/severe vs. normal anxiety and depression [1.11, 0.64–1.94]).
Adjustment for age, marital status, education level and birth-
place, gave virtually identical results (mild vs. normal anxiety
and depression scores [0.96, 0.70–1.31] and moderate/severe
vs normal anxiety and depression scores [1.14, 0.65–2.02]),
that is, there were no differences in anxiety and depression
scores and screening arms. When we compared the different
screening test outcomes with normal cytology (being the most
common screening test results in NCCSP), we found no statis-
tically significant differences neither in univariate nor in mul-
tivariate models between any screening test results and mild
vs. normal anxiety depression scores nor between moderate/
severe vs. normal anxiety and depression scores. Women in
the cytology arm having the diagnosis ASC-US and in addi-
tion being hrHPV negative had results in univariate models
and multivariate models, respectively: (mild vs. normal anxiety
and depression scores [1.11, 0.68–1.81; 1.05, 0.64–1.74]
and moderate/severe vs. normal anxiety and depression scores
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Figure 3. Scores of anxiety and depression among 966 women with different screening test results (496 from the cytology arm and 470 from
the hrHPV arm) (a) Grouped presentation of anxiety and depression scores between screening arm (b) Distribution of anxiety and depression
scores between seven different screening diagnoses and between comparable diagnosis in the cytology and the hrHPV arm respectively. The
percentage are calculated in the cytology and the hrHPV-arm, respectively, *HG = high-grade cytology. [Color figure can be viewed at
wileyonlinelibrary.com]
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[0.91, 0.36–2.26; 0.93, 0.37–2.38]). Women in the cytology
arm having the diagnosis ASC-US and in addition being
hrHPV positive had in univariate and multivariate models
results, respectively: (mild vs. normal anxiety and depression
scores [1.22, 0.60–2.47; 1.10, 0.53–2.25] and moderate/severe
vs. normal anxiety and depression scores [0.69, 0.15–3.20;
0.62 0.13–2.94]). Women in the cytology arm having a high-
grade cytology had in the univariate and multivariate models,
respectively (mild vs. normal anxiety and depression scores,
(0.94, 0.44–2.02; 0.73, 0.33–1.60) and moderate/severe vs. nor-
mal anxiety and depression scores (1.04, 0.28–3.82; 0.95,
0.25–3.63)). Women in the hrHPV arm being hrHPV nega-
tive had in univariate and multivariate models, respectively
(mild vs. normal anxiety and depression scores [0.77,
0.48–1.24; 0.79, 0.48–1.28] and moderate/severe vs. normal
anxiety and depression scores [0.99, 0.45–2.21; 1.07,
0.47–2.43]). Women in the hrHPV arm being hrHPV posi-
tive and having normal cytology had results in univariate
and multivariate models, respectively (mild vs. normal anxi-
ety and depression scores [1.27, 0.79–2.04; 1.15, 0.70–1.87]
and moderate/severe vs. normal anxiety and depression
scores [0.89, 0.36–2.22; 0.87, 0.34–2.23]). Finally, women in
the hrHPV arm being hrHPV positive and having ASC-US
or more severe cytology diagnoses had in univariate and
multivariate models, respectively: (mild vs. normal anxiety
and depression scores [1.15, 0.62–2.13, 1.00, 0.53–1.90] and
moderate/severe vs. normal anxiety and depression scores
[1.41, 0.51–3.88, 1.31, 0.46–3.78]). To sum up, we found no
difference in anxiety and depression scores neither between
women in the two screening arms nor between women with
different screening diagnosis.
We performed stratified analyses to further investigate
whether anxiety and depression scores were associated with
time elapsed between when the women were informed about
their last screening test results and when they answered the
questionnaire. There was no interaction between elapsed time
and screening arm (p = 0.11) nor between elapsed time and
screening results (p = 0.39). Stratified analyses by elapsed time
can be found in the Supporting Information Table S1.
Separate analyses of the anxiety and the depression dimen-
sions of the PHQ-4-score showed no difference by screening
arm or by screening test result on anxiety scores, or on
depression scores (Supporting Information Table S2).
Discussion
In this cross-sectional study, we compared mild vs. normal
anxiety and depression scores as well as moderate/severe anxi-
ety and depression scores vs. normal, among women, 34 years
and older, tested by cytology or hrHPV in primary screening.
We found no difference in long-term (4–24 months after the
screening) anxiety and depression scores as measured by the
PHQ-4 scale between the two groups. Seven different combi-
nations of screening test results were possible outcomes in the
implementation project. There were no statistically significantTa
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differences in long-term anxiety and depression scores
between women receiving each of these different screening
results.
A concern when changing test method in a screening pro-
gramme is whether the new test could influence screening
participation negatively and psychological distress might
potentially lead to reduced participation.28 The literature is
inconsistent regarding anxiety and depression related to
hrHPV testing in cervical cancer screening and its impact on
screening participation. The results from our study are coincid-
ing with a large randomized trial from Manchester in 2008
enrolling 24,510 women. our study found no adverse signifi-
cant psychological effect on routine hrHPV screening as com-
pared to cytology screening.29 This lack of association between
HPV screening and psychological distress might be explained
by what is found in three other studies30–32 showing that anxi-
ety and depression is first and foremost linked to having abnor-
mal screening results and not to the screening method used. In
contrast to this, a systematic review of 17 studies in 2012 con-
cluded that hrHPV testing could indeed increase anxiety,
impact relationships and provoke fear of stigmatization.33 This
review and several other studies have linked women’s experi-
ences of anxiety to reflections around stigma as HPV infections
are sexually transmitted.13,34 In concordance to our study,
where hrHPV was the primary screening test, the women in
the above-mentioned studies13,34 knew that they had an abnor-
mal cytology, and the hrHPV test was part of follow-up.
The vast majority of women taking part in our study knew
that screening can prevent—and that an HPV infection can
cause—cervical cancer. However, most women did not know
which method was used in their last screening test. This was
the case even though information campaigns in mass media
and at health centers had been carried out prior to the initia-
tion of the implementation project of hrHPV as primary
screening method, suggesting that the information strategy did
not fully succeed in enlightening the women targeted for
screening. This should be taken into consideration when inter-
preting these results.
Half of the participants in the present study said they
would seek screening tests more often than every year if the
programme’s screening interval were to be expanded from
3 to 5 years. This may reflect women’s fear that a 5-year inter-
val might be unsafe. However, to expand the screening inter-
val from 3 to 5 years using hrHPV testing in primary
screening is considered safer than a 3-year interval with con-
ventional primary cytology screening according to different
studies.18,35 However, this fact is not currently known among
women targeted by the national cervical cancer screening pro-
gramme in Norway. Our findings are in line with those from
a modeling study in Australia. 36 The Australian study indi-
cated that extended screening intervals when adopting hrHPV
testing as primary screening method is expected to lead to
fluctuation in screening participation of about 50% in the
first 5-year period. A screening programme where over half of
the women seek opportunistic screening would entail unnec-
essary use of healthcare services and costs. Therefore, further
efforts are needed to provide women with accurate and under-
standable information about the HPV infection and the safely
of expanding screening intervals with the introduction of
hrHPV testing in primary screening.18,25 Information must
necessarily be tailored to match women’s needs to be effec-
tive.37 Moreover, knowledge has the potential to reduce nega-
tive psychological outcomes.38–40 Interestingly, in our study
women in the hrHPV arm had significantly more knowledge
about their own screening test results than women in the
cytology arm. This may be because women in the hrHPV arm
who were hrHPV negative received an additional information
letter from the CRN,3 including information about the
method used and the extended screening interval. The differ-
ence in knowledge could also be because women who are tested
with hrHPV and women who are hrHPV positive tend to seek
information about screening test results more actively than
women who are tested with cytology.12,33 This may also indi-
cate that the information given related to screening test results
raised awareness about the screening procedures and outcomes.
Strengths and limitations
Our study has several limitations. The PHQ-4 scale is a gen-
eral tool for detecting symptoms of anxiety and depression; as
such it does not include questions related to cervical cancer
screening or its procedures. Women answered the question-
naire 4 months to 2 years after receiving their last screening
result, and any anxiety and depression they might have felt
closer in time to screening participation could have faded by
the time they took part in the study. Another possible limita-
tion in our study is non-response bias, as individuals who
chose to answer the questionnaire may differ from nonre-
sponders. Nonresponse is unlikely to differ between arms but
may have reduced the representability of the study’s sample.
We did not find any significant associations in the study,
but some RRR’s were somewhat elevated for example, women
in the hrHPV arm had a nonsignificant 14% increased risk of
experiencing moderate/severe anxiety and depression scores
as compared to women in the cytology arm (Table 2). Due to
the limited number of study participants, we cannot entirely
rule out that a difference exists but was not revealed due to
lack of statistical power.
The entire questionnaire was piloted only among women
working at the CRN, a select group likely more aware of
health-related issues than the general population. However,
the women involved in the pilot were asked to try to look at
the questionnaire as if they did not have their professional
knowledge, and many good suggestions and subsequent
changes were made as a result of this piloting process. Thus,
we do not know whether some of the questions were difficult
to understand among other women. The PHQ-4 score was,
however, a validated screening tool for measuring anxiety and
depression.
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Despite randomization, there were some differences between
screening arms regarding marital status and birthplace, and
these differences were therefore adjusted for in the two multi-
nomial logistic regression models. Finally, the survey question-
naire was answered at a single point in time, and any changes
in anxiety and depression over time were not assessed.
Prior to the onset of the hrHPV pilot project, information
campaigns regarding HPV had been delivered in mass media
and at doctors’ offices, and additional information was deliv-
ered from the CRN to women randomized into the hrHPV
testing arm only. This may have contributed to raise the level
of knowledge among women in the hrHPV testing arm, thus
making these women more prepared to deal with an abnormal
screening test result than women in the cytology arm. This
might at least partially explain the difference in knowledge we
found between arms in our study.
The study also has several strengths. It was conducted on a
large sample, and anxiety and depression scores were measured
in a real-life situation (and not only hypothetically as in the
previously published study.9) Women with positive screening
results were oversampled by design, which might have led to
higher anxiety and depression scores compared to that in the
general population. However, the lifetime occurrence of anxiety
and depression among participants in our study are fairly simi-
lar to the prevalence of anxiety and depression found among
Norwegian women.
Conclusions
In our study, we have compared long-term (4–24 months after
the screening) anxiety and depression scores between women
34 years and older undergoing primary cervical cancer screening
with cytology and hrHPV testing. We found no differences in
anxiety and depression scores between the two groups measured
from 4 months to 2 years after women had received their last
screening test result. We conclude that there are no indications
that screening participation will be adversely affected by anxiety
and depression nor that hrHPV testing in primary screening
would make women have more anxious and/or depressed symp-
toms than conventional cytology screening.
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